Navigation Links
Kensey Nash Announces Mediated Settlement With St. Jude Medical in Angio-Seal License Disputes and 5 Year Extension and Expansion of Collagen Supply Agreement
Date:3/16/2012

uidance" and similar expressions, but these words are not the exclusive means for identifying such statements.  The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those expressed in, or implied by, the forward-looking statements, including, without limitation, St. Jude's success in selling the Angio-Seal device and the extent to which St. Jude Medical is able to and does in fact rely on its internal manufacturing to fulfill its requirements for collagen plugs for the Angio-Seal device in excess of the contractual minimums under the Company's extended collagen supply agreement with St. Jude, the success of the Company's other customers and partners (including Arthrex, Stryker and Synthes) in selling Kensey Nash related products in the marketplace, the Company's success in its research and development efforts (including in its cartilage repair, extracellular matrix and adhesive materials programs), the Company's success in and the uncertainty of transitioning the Norian manufacturing operations to the Company and Synthes' success in distributing the Norian products, the success of clinical trials in both the U.S. and outside the U.S. to support regulatory approval of the Company's products, and competition from other technologies, as well as tax and other risks associated with healthcare reform, economic conditions and foreign currency fluctuations.  For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosures under "Risk Factors" in those filings.  Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

Non-GAAP Financial Measures and Reconciliations


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kensey Nash Announces IDE Submission for Cartilage Repair Device
2. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
4. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
5. Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
6. Kensey Nash Announces $30 Million Share Buyback
7. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
8. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
9. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
10. Kensey Nash to Present at the Ninth Annual JMP Securities Research Conference
11. KENSEY NASH Receives FDA 510(k) Clearance for ECM Product, Meso BioMatrix Surgical Mesh
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Bruin Biometrics (BBI), a pioneer in biometric-sensor ... weeks of clinical briefings to over 200 pressure ... substantial concurrence on both the clinical validity of ... BBI,s SEM Scanner. "From our ... drawn from the European Wound Management Association (EWMA) ...
(Date:7/24/2014)... -- As part of its ongoing effort to help women pharmacists ... Ownership Boot Camp on July 26 as part of the ... D.C. The Boot Camp is designed ... own their own pharmacies.  Now in its third year, the ... women pharmacists who dream of owning a pharmacy.   ...
(Date:7/24/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, reported interim results in a Phase 2a ... as a treatment for metastatic renal cell carcinoma ... one therapy involving a VEGF inhibitor (e.g., Sutent®/ ... inhibitor (e.g., Afinitor®/everolimus), with a maximum of three ...
Breaking Medicine Technology:Bruin Biometrics Secures Support of EU Scientific Community for its SEM Scanner Technology 2'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 2'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 3'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 4Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4
... SHANGHAI, Feb. 21, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... leading China-based pharmaceutical and biotechnology research and development outsourcing ... Annual Health Care Conference, to be held in Boston, ... Xie, Vice President of Finance and Investor Relations of ...
... 2012  NewCrop LLC has selected Verizon Enterprise ... NewCrop,s new electronic system for prescribing controlled ... tailored digital identity solution, Verizon Universal ... submit electronic prescriptions for controlled substances via ...
Cached Medicine Technology:NewCrop Chooses Verizon to Help Provide Secure Electronic Prescriptions for Controlled Substances 2NewCrop Chooses Verizon to Help Provide Secure Electronic Prescriptions for Controlled Substances 3
(Date:7/24/2014)... 2014 (HealthDay News) -- Even though its use is often ... Tylenol -- does not help treat lower back pain, according ... the drug was no more effective than a dummy pill ... pain. Besides showing no effect in easing discomfort, the ... sleep woes tied to back pain, nor did it improve ...
(Date:7/24/2014)... Attendances at emergency departments can be reduced by enabling ... visit their doctor,s surgery. This is just one of ... by researchers at the University of Bristol. , Called ... of systematic reviews, the report has been compiled by ... who looked at evidence from studies around the world. ...
(Date:7/24/2014)... have identified two previously undescribed radiological signs ... gastric bands. Adding widespread knowledge of the ... margin by more than 2.4 cm from ... air-fluid,level above the band on a frontal ... in diagnosing affected bariatric patients. These signs ...
(Date:7/24/2014)... Insecticides similar to nicotine, known as neonicotinoids, were ... to a new USGS study. This is the ... Midwestern United States and one of the first ... killing a broad range of insect pests, use ... last decade across the United States, particularly in ...
(Date:7/24/2014)... The National Resident Matching Program (NRMP) ... version of its smartphone app, The MATCH Program Rating ... in NRMP’s Main Residency Match® and Specialties Matching Service®. ... information during the interview process and develop program ratings ... lists. Rank order lists are used by the ...
Breaking Medicine News(10 mins):Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3Health News:Seeing the same GP at every visit will reduce emergency department attendance 2Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 3
... (NAFLD) have suboptimal levels of cardiovascular fitness, muscle strength, ... study. The findings appear in the April issue of ... Study of Liver Diseases (AASLD). The article is also ... , About one-in-four U.S. adults suffers from NAFLD, which ...
... Attributes encouraged in the trials process may improve overall ... -- Patients with heart attacks or other acute heart ... rates in hospitals that take part in clinical trials, ... than 174,000 patients with two types of heart conditions ...
... offering the best for its gifted students and staff members,Stanford ... machines, which are geared towards natural and ... of Solana Beach, Ca,YoNaturals Inc. was launched in August of ... have been committed, from the start, to providing,its customers with ...
... for Healthcare ... Professionals, HADDON ... malignant type of glioma. Healthcare professionals,face many challenges in the treatment ... in patients is less than,one year., Recent clinical trials have ...
... Mass., March 24 Andover,Medical, Inc. (OTC Bulletin Board: ... ("DME"), announced today that the,Company anticipates closing a $2.0 ... of the financing can be,found in the Company,s Form ... and,available at http://www.sec.gov ., On March 13, ...
... -- Heart damage due to blocked arteries remains the leading ... a Florida State University College of Medicine researcher is helping ... Blaber, a professor in the department of biomedical sciences, is ... shown to help the human body grow new blood vessels ...
Cached Medicine News:Health News:Study finds certain liver disease related to cardiovascular fitness 2Health News:Patients Do Better at Hospitals With Clinical Trials 2Health News:YoNaturals to Install Healthy Vending Machines at Stanford University 2Health News:Adult Glioblastoma: Strategies, Challenges, and Opportunities 2Health News:Andover Medical, Inc. Anticipates Closing $2.0 Million Private Financing 2Health News:Andover Medical, Inc. Anticipates Closing $2.0 Million Private Financing 3Health News:FSU researcher's 'mutant' proteins could lead to new treatment for heart disease 2
Gently curved shaft with blunt angled tip is ideal for chopping the lens during anterior chamber phacoemulsification....
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique to be used in left hand. Round knurled handle....
Flat 7 mm wide hook. Flat serrated handle with polished finish. Overall length: 5.1 inches....
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
Medicine Products: